Hemosol submits blood substitute in Canada
This article was originally published in Clinica
Executive Summary
Biotech company Hemosol has submitted for Canadian marketing approval its Hemolink blood substitute for use in coronary artery bypass grafting. The Toronto, Ontario firm believes it is the first to have filed a marketing application for a human blood substitute in North America.